William J. Rieflin
Mr. Rieflin became Chairman of NGM’s Board of Directors in July 2022. Prior to his role as Chairman, Mr. Rieflin served as Executive Chairman of NGM’s Board of Directors since September 2018 after having served as Chief Executive Officer of the company and a member of the Board over the prior eight years. Prior to joining NGM, he was President of XenoPort, Inc. (NASDAQ: XNPT), which was acquired by Arbor Pharmaceuticals in 2016, and Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary for Tularik Inc. (NASDAQ: TLRK), which was acquired by Amgen Inc. in 2004. Previously, he was Vice President, Human Resources, General Counsel and Secretary for AMSCO International, Inc. (NYSE: ASZ). He was also an associate at Sidley & Austin in the corporate and securities department. He began his career as a sales representative for American Hospital Supply Corporation. He currently serves as Chair of the Board of Directors for Lycia Therapeutics, Inc., and also serves on the Board of Directors of RAPT Therapeutics, Inc (NASDAQ: RAPT)., Lyell Immunopharma, Inc. (NASDAQ: LYEL), and Kallyope, Inc. Mr. Rieflin earned his B.S. from Cornell University, his M.B.A. from the University of Chicago Booth School of Business and his J.D. from Stanford Law School.